116 related articles for article (PubMed ID: 24068396)
21. Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma.
Pyo JS; Kang G; Kim DH; Chae SW; Park C; Kim K; Do SI; Lee HJ; Kim JH; Sohn JH
Pathol Res Pract; 2013 Apr; 209(4):228-32. PubMed ID: 23528368
[TBL] [Abstract][Full Text] [Related]
22. Association of Cancer Stem Cell Markers With Aggressive Tumor Features in Papillary Thyroid Carcinoma.
Lin Z; Lu X; Li W; Sun M; Peng M; Yang H; Chen L; Zhang C; Cai L; Li Y
Cancer Control; 2015 Oct; 22(4):508-14. PubMed ID: 26678979
[TBL] [Abstract][Full Text] [Related]
23. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
24. [The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma].
Xue G; Huang J; Zhang H; Zhang W; Wu J; Shang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jan; 28(2):108-12. PubMed ID: 24738314
[TBL] [Abstract][Full Text] [Related]
25. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
27. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
Meng Z; Lu J; Wu H; Zhao Y; Luo Y; Gao J; Zhu Q; Jiang Y; Li W; Liang Z
Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
[TBL] [Abstract][Full Text] [Related]
28. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
29. [The study of the correlation of papillary thyroid carcinoma's invasion toward Ezrin and E-cadherin].
Liu C; Chen X; Gao Z; Liu Z; Tao X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Sep; 26(17):789-91, 795. PubMed ID: 23214316
[TBL] [Abstract][Full Text] [Related]
30. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
[TBL] [Abstract][Full Text] [Related]
32. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
Lee JJ; Wang TY; Liu CL; Chien MN; Chen MJ; Hsu YC; Leung CH; Cheng SP
J Clin Endocrinol Metab; 2017 Aug; 102(8):2930-2940. PubMed ID: 28575350
[TBL] [Abstract][Full Text] [Related]
34. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
35. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
36. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
37. Co-expression and clinical utility of Snail and N-cadherin in papillary thyroid carcinoma.
Yang X; Shi R; Zhang J
Tumour Biol; 2016 Jan; 37(1):413-7. PubMed ID: 26219900
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
39. Cribriform-morular variant of papillary thyroid carcinoma in an 8-year-old girl: a case report with immunohistochemical and molecular testing.
Rossi ED; Revelli L; Martini M; Taddei A; Pintus C; Panunzi C; Fadda G
Int J Surg Pathol; 2012 Dec; 20(6):629-32. PubMed ID: 22494995
[TBL] [Abstract][Full Text] [Related]
40. Expression of Spindle and Kinetochore-Associated Protein 1 Is Associated with Poor Prognosis in Papillary Thyroid Carcinoma.
Dong C; Wang XL; Ma BL
Dis Markers; 2015; 2015():616541. PubMed ID: 26063960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]